Chemical Raw Materials Become The Focus Of Fine Chemicals

Chemical Raw Materials Become The Focus Of Fine Chemicals

This year, the industry associations regard fine chemicals as the main article. Comparing this year to the fine chemicals year is not excessive. The chemical raw material is a ruler measuring the fine chemical industry to what extent. China has long been based on uneducated effigy on chemical raw materials, for the production is extensive, export portion and partly no innovation. China chemical raw materials taking this extensive flowering path, it is difficult to maintain protracted and rapid hike, thereupon, it will become an important belief in the fine chemicals year.
In the new year, the export of chemical raw materials are blocked, low - match economic development striving, major competition and other orderly areas of multiple challenges. In recent years, Chinese people, the production cost and other advantages are attracting mission pharmaceutical giant, the raw material drug production to China. Chinese enterprises are differing more pressure.
China is the world ' s largest determinant of bulk drugs and capable of efficacious more than 1500 kinds of bulk drugs. The varieties are greatest in the world. Meanwhile, China is the world ' s largest exporter of chemical raw materials, bulk drugs exports of domestic production accounted for partly half. Since 2001, China ' s API exports an average annual compound extension percentage of more than 20 %. In 2008, total export situation of China ' s API is $ 23. 894 billion, an increase of 22. 19 %. Which exports reached $ 17. 58 billion, an increase of 29. 59 %, and profit increase of about 50 %. Export of bulk drugs industry pulling effect is conspicuous.
But since 2009, API is the industry ' s first negative aggrandizement statistics make this area known as the export haven filled with the response. 1 November last year, China ' s total export of chemical raw materials for the $ 14. 87 billion, down by 7. 35 %. In major export markets, exports to Asia, 64. 8 million U. S. dollars, down 3. 24 %; Europe 42. 5 billion U. S. dollars, down 11. 86 %; North America for $ 2. 27 billion, down 11. 83 %. Over the gone five years, China is the first negative stretching in exports of chemical raw materials octylferrocene. In detail, do not fly to export as a safe haven is planned. In the financial turmoil sweeping the world direction, the deterioration of the international economic environment inevitably affect the export of chemical raw materials. Homologous as Africa, Nigeria, half due to exchange ratio depreciation, local buyers can plan payments to Chinese enterprises has caused tremendous losses. India, Europe, the supply of medicines in Africa decreased significantly, resulting in a further decline in demand for bulk drugs, lower prices. Higher cause for the decline in exports more competition. India is China ' s raw materials, pharmaceutical intermediates and fine chemical products, the main export destination, accounting for China ' s total exports of pharmaceutical products 16. 5 %, after the United States. But India is also a Chinese chemical raw materials the company ' s competitors. Sino - Indian trade in the pharmaceutical and chemical class, there are some long - term anomaly: on the one hand, the Indian pharmaceutical companies need to import the raw material cost advantage of Chinese medicine with intermediate; the other hand, India has worried about the rapid development of Chinese chemical raw materials industry, China ' s raw material Indian drug will occupy most of the market. In consequence, below the ideological influence of trade protection, reduction and boycott Chinese imports of pharmaceutical products to become the major forces in the Indian market. Within the elapsed year, India twice on the production of penicillin industrial spiciness from China initiated anti - dumping investigations. This is the fruition of chemical raw materials for Chinese exports to India, an important impetus for the decline. Further, this phenomenon also will maintain.
Although countries in the UN Climate Pocket money Conference in Copenhagen reached only on a non - legally binding agreement, but by kind energy efficiency and reduce angel emissions to combat climate pin money has become the unity of the world. In this point, the " three low - mode " ( low efficacy consumption, low emissions ) and low - likeness economy, low - match development and a series of new concepts and new policy will come into being. Released in China to wrap up the big idea to control greenhouse gas emissions targets, only 40 % to 45 % emission reduction target, also referred to speed up the construction industry is characterized by a low - appearance system. Thus, a low spitting image is characterized by the pharmaceutical manufacturing industry industrial system as described perspective for future development are an important sum.
Pharmaceutical industry is one of China ' s enormous polluting industries. In 2003, China will pharmaceutical included in the list of heavily polluting industries. As the synthetic bulk drugs and bulk drugs production fermentation process produces the " three wastes " more. While vitamin C and penicillin both Chinese medicine raw materials sub - sectors included in the bulk limit the development of class projects.
Chemical raw materials industry " exports, the pollution unsocial behind " feature has been the belief of criticism. As of pollution, developed many years ago put the high pollution and low aggrandized monetary worth of the chemical raw materials industries to Third World countries. China is also in the globalization of the industrial disjunction to occasion a number of high pollution, high energy consumption industries. Profits of the main export of chemical raw materials industry, described the Chinese pharmaceutical manufacturing industry in the most polluted industry - its export - oriented products, while consumption in other countries, China is carrying resource consumption and model emissions double the price.
All the signs make out that the low - icon manufacturing, the pharmaceutical industry structural reconciliation era has come, the Chinese chemical raw pharmaceutical companies how to achieve low - copy has become an paramount subject.
Italian imitation of the latest CPA report, the global market of chemical raw materials in 2004 was 680 billion U. S. dollars, and by 2008 more than $ 90 billion, of which the global generic sales in 2008 reached $ 78 billion over the previous year maturation of 4 %. The inducement why the world ' s optimistic generic drug market, because each innovation in drug development costs up to 30 million to 1. 6 billion U. S. dollars, the market course to be 5 to 8 years, and R & D success scale of a million. Faced with compatible a high threshold to enter the person singular. To entail generic drugs, including generic drugs to meet the needs of most diseases today, the price was only about 10 % of deviceful drugs. In addition, the world is antithetical pressure to reduce health costs of the original
Also makes generic drugs favored by. Currently the world are surviving to reduce medical costs, corresponding as France are forced to cut prices 40 % of the drugs, the United States in many therapeutic areas to reduce drug prices, many Chinese medicines has also been included in the price ceiling directory. All this makes the global pharmaceutical industry to find new more cost - competitive generic market.
Generic is China ' s median sector of chemical raw materials enterprises. China is a sizeable country with generic drugs Musk R - 1, in the elapsed China has approved more for generic drugs. China ' s pharmaceutical enterprises are mainly based on the production of generic drugs, a immense number of patented drug concentrations due, no doubt for the chemical raw materials business development opportunities. However, this opportunity is equal, Chinese enterprises welcome development opportunities at the same time, foreign companies have long coveted a long time for this opportunity. In particular, China ' s new medical reform will be implemented low - level, wide coverage of health insurance policy, the future market demand for quality and cheap generic drugs will become more urgent. Many interest companies have chemical raw materials to China, the generics market as a key research mark. Foreign enterprises in the overall quality of generic drugs has perceivable advantages, especially motley and difficult for generic drugs has technical advantages. In addition, they are thoroughly international pharmaceutical market research, access to medical resources, drug information quickly and efficiently for the generic drug patent termination helps to grasp the market opportunities.
In differentiation, although China is a big generics country, it is still not a really powerful country on generic drugs. Industry experts point out that the majority of Chinese chemical raw products are still in the extensive stage of imitation, double as in the processing and transformation. If Chinese enterprises want to seize opportunities in the development of generic drugs in China and make competition with foreign giants or even the world market, they must vigorously strengthen the quality of manufacturing technology management and technology innovation.